Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is viewed favorably because it combines clear market leadership in robotic surgery with a deeply entrenched ecosystem, more than 11,000 da Vinci systems installed worldwide, and over 16 million procedures performed globally, which together create strong switching costs and a durable competitive moat. Its fundamental growth thesis is supported by broad adoption drivers such as rising patient demand, staffing shortages, and the advantages of minimally invasive surgery, while multiple platforms, new product cycles, and the extended use program should expand the total addressable market and reinforce utilization over time. Financially, the company delivered Q2’26 revenue of $2.89B, EPS of $2.80, gross margin of 70.0%, and operating margin of about 42%, underscoring best-in-class profitability, operating leverage, and resilient execution despite near-term U.S. headwinds.

Intuitive Surgical is facing a less favorable fundamental setup as its once-premium valuation has deteriorated amid increased competition, economic and capital spending pressure, and limited procedure growth. U.S. da Vinci procedure growth moderated to 12% y/y in Q2’26, while barriers from elective deferrals, GLP-1 headwinds in bariatrics, and hospital budget constraints could slow installed-base expansion and system sales. Although international growth remains stronger at 20% y/y and the ecosystem is still dominant, China’s pricing pressure, lower tender activity, and competitive intensity add meaningful risk to earnings durability.